WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in China, the United States, Ireland, Germany and Singapore, WuXi Biologics leverages its technologies and expertise to provide customers with efficient and cost-effective biologics discovery, development and manufacturing solutions. As of June 30, 2023, WuXi Biologics is supporting 621 integrated client projects, including 22 in commercial manufacturing.
WuXi Biologics views Environmental, Social, and Governance (ESG) responsibilities as an integral component of our ethos and business strategy, and we aim to become an ESG leader in the biologics CRDMO sector. Our facilities use next-generation biomanufacturing technologies and clean-energy sources. We have also established an ESG committee led by our CEO to steer the comprehensive ESG strategy and its implementation, enhancing our commitment to sustainability.
Related Websites
-
Guangzhou Trauer Biotechnology Co.,LTD
Update time: 2024-01-21 -
Wuhan Easy Diagnosis Biomedicine Co., Ltd
Update time: 2024-01-21 -
Anhui Aerospace Biotechnology Co.,Ltd.,
Update time: 2024-01-21 -
Qingdao Vland Biotech INC.
Update time: 2024-01-21 -
Layn Natural Ingredients | Layn Corp
Update time: 2024-01-21 -
Shandong Meizheng Bio-Tech Co.,Ltd
Update time: 2024-01-21 -
Beijing Strong Biotechnologies, Inc.
Update time: 2024-01-21 -
Guangzhou Jet Bio-Filtration Co., Ltd
Update time: 2024-01-21 -
Zhejiang Dayang Biotech Group Co., Ltd.
Update time: 2024-01-21 -
Zhongshi Duqing (Shandong) Biotechnology Co., Ltd.
Update time: 2024-01-21